Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Hits New 1-Year Low – What’s Next?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s share price hit a new 52-week low on Tuesday . The company traded as low as $6.69 and last traded at $6.76, with a volume of 1245038 shares changing hands. The stock had previously closed at $6.80.

Wall Street Analysts Forecast Growth

Separately, Bank of America upgraded shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a report on Friday, September 6th. One research analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. Based on data from MarketBeat.com, Bayer Aktiengesellschaft has a consensus rating of “Hold”.

Bayer Aktiengesellschaft Stock Performance

The company has a quick ratio of 0.86, a current ratio of 1.27 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $26.56 billion, a price-to-earnings ratio of -18.78 and a beta of 1.10. The stock’s 50-day simple moving average is $7.60 and its 200 day simple moving average is $7.47.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.25 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.25. The firm had revenue of $12 billion during the quarter. Bayer Aktiengesellschaft had a positive return on equity of 16.96% and a negative net margin of 2.74%. Analysts expect that Bayer Aktiengesellschaft will post 1.38 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.